Skip to main content
Fig. 4 | Cancer Cell International

Fig. 4

From: Contribution of nuclear BCL10 expression to tumor progression and poor prognosis of advanced and/or metastatic pancreatic ductal adenocarcinoma by activating NF-κB-related signaling

Fig. 4

Silencing of BCL10 significantly inhibited tumor growth of PDAC in a xenograft model. a Approximately 1 × 106 scrambled (Scr) PANC-1 cells and shBCL10-treated PANC-1 cells were implanted subcutaneously into both flanks of NOD/SCI D mice. Representative image shows that the xenograft tumor size was suppressed in shBCL10-treated group. Mice were sacrificed 6 weeks after implantation. Scale bar: 10 mm. b The shBCL10-treated group resulted in 78% reduction of xenograft tumor volume compared with scrambled group. The results of tumor volume are expressed as n = 6 in each treatment group and measured each week. ***p < 0.001, compared to scrambled group. c There is almost no difference in body weight between scrambled group and shBCL10-transfected group. d The expression patterns of BCL10, BCL3, and NF-κB in tumor samples of PANC-1-xenograft model (upper panel, scrambled group; lower panel, shBCL10-treated group). PDAC pancreatic ductal adenocarcinoma

Back to article page